image
Healthcare - Medical - Devices - NASDAQ - US
$ 69.15
2.19 %
$ 2.33 B
Market Cap
64.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMDX stock under the worst case scenario is HIDDEN Compared to the current market price of 69.2 USD, TransMedics Group, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMDX stock under the base case scenario is HIDDEN Compared to the current market price of 69.2 USD, TransMedics Group, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TMDX stock under the best case scenario is HIDDEN Compared to the current market price of 69.2 USD, TransMedics Group, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TMDX

image
$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
442 M REVENUE
82.74%
37.5 M OPERATING INCOME
230.53%
35.5 M NET INCOME
100.00%
48.8 M OPERATING CASH FLOW
474.60%
-129 M INVESTING CASH FLOW
33.33%
22.9 M FINANCING CASH FLOW
-94.29%
122 M REVENUE
11.83%
8.64 M OPERATING INCOME
120.34%
6.86 M NET INCOME
62.64%
19.7 M OPERATING CASH FLOW
186.76%
-13.6 M INVESTING CASH FLOW
71.51%
1.19 M FINANCING CASH FLOW
-84.91%
Balance Sheet TransMedics Group, Inc.
image
Current Assets 497 M
Cash & Short-Term Investments 337 M
Receivables 97.7 M
Other Current Assets 62.8 M
Non-Current Assets 307 M
Long-Term Investments 0
PP&E 292 M
Other Non-Current Assets 14.4 M
41.87 %12.15 %7.82 %36.37 %Total Assets$804.1m
Current Liabilities 59.9 M
Accounts Payable 10.3 M
Short-Term Debt 2.73 M
Other Current Liabilities 46.9 M
Non-Current Liabilities 516 M
Long-Term Debt 456 M
Other Non-Current Liabilities 59.4 M
8.15 %79.27 %10.32 %Total Liabilities$575.5m
EFFICIENCY
Earnings Waterfall TransMedics Group, Inc.
image
Revenue 442 M
Cost Of Revenue 179 M
Gross Profit 262 M
Operating Expenses 225 M
Operating Income 37.5 M
Other Expenses 2.03 M
Net Income 35.5 M
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00442m(179m)262m(225m)37m(2m)35mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.36% GROSS MARGIN
59.36%
8.49% OPERATING MARGIN
8.49%
8.03% NET MARGIN
8.03%
15.51% ROE
15.51%
4.41% ROA
4.41%
4.98% ROIC
4.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TransMedics Group, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 35.5 M
Depreciation & Amortization 19.8 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others 48.8 M
Free Cash Flow 48.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TransMedics Group, Inc.
image
Wall Street analysts predict an average 1-year price target for TMDX of $152 , with forecasts ranging from a low of $90 to a high of $208 .
TMDX Lowest Price Target Wall Street Target
90 USD 30.15%
TMDX Average Price Target Wall Street Target
152 USD 119.61%
TMDX Highest Price Target Wall Street Target
208 USD 200.80%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100808060604040May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership TransMedics Group, Inc.
image
Sold
0-3 MONTHS
184 K USD 1
3-6 MONTHS
965 K USD 2
6-9 MONTHS
19.7 M USD 6
9-12 MONTHS
43.2 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit – TMDX NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141589&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit - TMDX NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141565&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
TMDX DEADLINE NOTICE: Lose Money when TransMedics Group Stock Plummeted 30%? Contact BFA Law before April 15 Class Action Deadline NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. accessnewswire.com - 1 week ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of TransMedics Group, Inc. (TMDX) Shareholders NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141537&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Ibotta, Inc. (NYSE: IBTA) NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE: IBTA) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. globenewswire.com - 1 week ago
Class Action Filed Against TransMedics Group, Inc. (TMDX) Seeking Recovery for Investors - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141518&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Ongoing Investigation Into Reckitt Benckiser Group PLC (OTC: RBGLY) NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. globenewswire.com - 1 week ago
TMDX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), have until Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics and of TransMedics' executives with violations of the Securities Exchange Act of 1934. globenewswire.com - 1 week ago
TransMedics Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - TMDX NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141494&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
TMDX Investors Have Opportunity to Lead TransMedics Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES , April 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ: TMDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 15, 2025. prnewswire.com - 1 week ago
Contact Levi & Korsinsky by April 15, 2025 Deadline to Join Class Action Against TransMedics Group, Inc. (TMDX) NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=141410&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 2 weeks ago
TMDX Stockholders Have Opportunity to Lead TransMedics Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired TransMedics securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). accessnewswire.com - 2 weeks ago
8. Profile Summary

TransMedics Group, Inc. TMDX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.33 B
Dividend Yield 0.00%
Description TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Contact 200 Minuteman Road, Andover, MA, 01810 https://www.transmedics.com
IPO Date May 2, 2019
Employees 728
Officers Dr. Tamer I. Khayal M.D. Chief Commercial Officer Mr. Anil Ranganath Senior Vice President, General Counsel & Corporate Secretary Mr. Gerardo Hernandez Chief Financial Officer Ms. Miriam C. Provost Ph.D. Vice President of Global Regulatory Affairs Dr. Waleed H. Hassanein M.D. Founder, President, Chief Executive Officer & Director Mr. Nicholas Corcoran Senior Vice President of Supply Chain & Operations